Loading
A phase 1/2 trial of VB15010 in ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma, biliary tract cancer and colorectal cancer, run by Zhejiang Yangli Pharmaceutical Technology Co., Ltd., now recruiting.
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06819215 by Zhejiang Yangli Pharmaceutical Technology Co., Ltd., with 188 participants planned, started 2024-10-30 and due to reach its primary completion in 2025-12-30. Interventions recorded: VB15010.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.